Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-016244
Filing Date
2025-06-09
Accepted
2025-06-09 16:18:04
Documents
1
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 form4-06092025_080659.html 4  
1 form4-06092025_080659.xml 4 4240
  Complete submission text file 0001415889-25-016244.txt   5910
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
Jimenez Freddy A. (Reporting) CIK: 0001838114 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-15006 | Film No.: 251034347